Scarica l'app Stockscreener
6.12
1.83%
0.11
Dopo l'orario di chiusura:
6.28
0.16
+2.61%
Precedente Chiudi:
$6.01
Aprire:
$6.09
Volume 24 ore:
505.34K
Relative Volume:
1.23
Capitalizzazione di mercato:
$131.53M
Reddito:
-
Utile/perdita netta:
$-30.54M
Rapporto P/E:
-3.9484
EPS:
-1.55
Flusso di cassa netto:
$-18.30M
1 W Prestazione:
+6.07%
1M Prestazione:
-6.99%
6M Prestazione:
+23.14%
1 anno Prestazione:
+721.59%
Intervallo 1D:
$5.87
$6.35
Intervallo di 1 settimana:
$5.36
$6.35
Portata 52W:
$0.45
$8.2457
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Nome
Unicycive Therapeutics Inc
Settore
Industria
Telefono
650-384-0642
Indirizzo
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
Confronta UNCY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
6.12 | 129.16M | 0 | -30.54M | -18.30M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-21 | Iniziato | Guggenheim | Buy |
| 2024-04-04 | Iniziato | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Borsa (UNCY) Ultime notizie
Will Unicycive Therapeutics Inc. stock maintain momentum in 2025July 2025 Earnings & Fast Moving Trade Plans - ulpravda.ru
Can Unicycive Therapeutics Inc. stock continue upward trendQuarterly Portfolio Review & Capital Efficiency Focused Ideas - ulpravda.ru
Unicycive Therapeutics Inc. (UNCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
News | Unicycive Therapeutics leases Mountain View offices - CoStar
How interest rate cuts could boost Unicycive Therapeutics Inc. stockMarket Trend Summary & Consistent Profit Trading Strategies - ulpravda.ru
How geopolitical tensions affect Unicycive Therapeutics Inc. stockBull Market Opportunities & Minimal Capital Investment - ulpravda.ru
Unicycive Therapeutics : January 2026 Corporate Presentation - MarketScreener
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Investors to Inquire about Securities Investigation - ACCESS Newswire
UNCY Stock Price, Forecast & Analysis | UNICYCIVE THERAPEUTICS INC (NASDAQ:UNCY) - Chartmill
What drives Unicycive Therapeutics Inc stock priceTrendline Breakouts & Let Our AI Be Your Trading Assistant - earlytimes.in
Maxim Group Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛
Guggenheim reiterates Buy rating on Unicycive stock amid NDA resubmission By Investing.com - Investing.com UK
Unicycive Therapeutics seeks FDA approval — again — for dialysis patients' phosphate treatment - The Business Journals
Unicycive resubmits NDA for hyperphosphatemia asset - Seeking Alpha
Unicycive Therapeutics announces resubmission of new drug application (NDA) for oxylanthanum carbonate (OLC) - MarketScreener
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) - TradingView — Track All Markets
Unicycive Resubmits New Drug Application for Oxylanthanum Carbonate - MarketScreener
Unicycive resubmits NDA for kidney disease treatment to FDA - Investing.com
Unicycive Therapeutics Resubmits NDA for Oxylanthanum Carbonate to FDA for Chronic Kidney Disease Treatment - Quiver Quantitative
Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum ... - Caledonian Record
Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate - MarketScreener
Companies Like Unicycive Therapeutics (NASDAQ:UNCY) Are In A Position To Invest In Growth - Yahoo Finance
Rally Mode: Can Unicycive Therapeutics Inc stock continue upward trendJuly 2025 Outlook & Fast Moving Stock Trade Plans - moha.gov.vn
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Shareholders to Connect - ACCESS Newswire
Why Unicycive Therapeutics Inc. stock is a must watch in 2025Trade Risk Summary & Verified Stock Trade Ideas - Улправда
Is Unicycive Therapeutics Inc. stock a top momentum playLong Setup & Smart Investment Allocation Insights - Улправда
Will Unicycive Therapeutics Inc. stock remain a Wall Street favorite2025 Biggest Moves & Long-Term Growth Stock Strategies - Bollywood Helpline
How Unicycive Therapeutics Inc. stock performs after earningsWeekly Market Outlook & High Accuracy Swing Trade Signals - Улправда
How Unicycive Therapeutics Inc. stock benefits from tech adoptionLong Setup & Daily Technical Forecast Reports - Улправда
Will Unicycive Therapeutics Inc. stock outperform Nasdaq indexQuarterly Portfolio Summary & Long-Term Growth Plans - Bölüm Sonu Canavarı
Can Unicycive Therapeutics Inc. stock deliver strong Q4 earningsJuly 2025 Weekly Recap & Consistent Profit Alerts - Улправда
Why analysts upgrade Unicycive Therapeutics Inc. stockEarnings Performance Report & Fast Exit Strategy with Risk Control - DonanımHaber
Aug Summary: Why Unicycive Therapeutics Inc. stock is a must watch in 20252025 Volume Leaders & Daily Technical Stock Forecast Reports - Улправда
Bragar Eagel & Squire is Investigating Certain Officers and - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Unicycive Therapeutics Earnings Notes - Trefis
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Chart Watch: Why analysts upgrade Unicycive Therapeutics Inc stock2025 Market Trends & Consistent Return Strategy Ideas - moha.gov.vn
Unicycive is all-in on kidney care, focusing on underserved areas: CEO - AlphaStreet
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Unicycive Therapeutics (UNCY) price target decreased by 12.88% to 47.43 - MSN
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Vivo Capital LLC Has $5.42 Million Stock Position in Unicycive Therapeutics, Inc. $UNCY - MarketBeat
Unicycive Therapeutics (NASDAQ:UNCY) Trading Up 5.6%Time to Buy? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Investors to Connect - ACCESS Newswire
Important Notice to Long-Term Shareholders of Five Below, - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Reach Out - ACCESS Newswire
Important Notice to Long-Term Shareholders of Cytokinetics, - GlobeNewswire
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office is Investigating Claims on Your Behalf - GlobeNewswire Inc.
Unicycive Therapeutics Inc Azioni (UNCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):